

 <p>STOP Notification</p>	<h2 style="color: #0070C0;">Path Review and HIS Revision</h2>	
When:	Tuesday, May 5, 2020	
What?	Change regarding schistocytes and path review	
Who is Affected:	Affected Location(s) x Alamance Cancer Center x High Point Cancer Center x Wesley Long Cancer Center x Alamance Regional x Annie Penn Hospital x MedCenter @ High Point x MedCenter @ Mebane x Moses Cone Hospital x Wesley Long Hospital Women's Hospital	Department(s) Blood Bank Cytology Flow Cytometry Histology Microbiology Phlebotomy Point Of Care x Rapid Response Lab Respiratory Therapy Specimen Processing
Why?	Pathologist review of existing criteria along with discussion of PLASMIC Score determined need to update/revise process for schistocyte review. Immediate discussion with pathology for non-CCtr sites was deemed necessary.	
What you will need to do to prepare:	Review changes to HIS and Path Review procedure that includes the following edits: <u>HIS:</u> REMOVED CCtr specific line: PLT <100 and schistocytes: Ask provider to consider adding LDH. ADDED non CCtr site line: PLT <100 and schistocytes: Refer to Path Review procedure. <u>Path Review procedure:</u> Non cancer center locations – ADDED immediate path review needed for presence of schistocytes with thrombocytopenia (plt <100) CCtr locations – ADDED when to submit for path review for presence of schistocytes: <b style="padding-left: 40px;">If schistocytes present as the main morphological abnormality and not associated with marked anisopoikilocytosis, submit for immediate path review. Otherwise comment that schistocytes are present with other morphologic descriptions without path review.	
Manager / Supervisor Responsibility:	Send Post Live Documentation to IT Manager within 5 days of the effective date for test systems marked with an "X"	
	Sunquest	WindowPath
	CHL	Instrument / Manual Test
	PowerPath	
Need Help?	Contact your Manager / Supervisor	